SCHEMBL12430666

SCHEMBL12430666

Cc1cc(Nc2nc(Nc3cccc(O)c3)nc3ccccc23)n[nH]1

nearest known ligand 0.81

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.81
SRC P12931 3/20 0.81
GSK3B P49841 3/20 0.81
NTRK1 P04629 11/20 0.61
PLK4 O00444 1/20 0.60
PAK4 O96013 1/20 0.60
AURKB Q96GD4 3/20 0.58
EIF2AK2 P19525 1/20 0.58
GSK3A P49840 1/20 0.58
TAAR1 Q96RJ0 1/20 0.57
NTRK3 Q16288 1/20 0.56
NTRK2 Q16620 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430654 0.90 AURKA (1.00) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12430710 0.89 AURKA (0.84) AURKASRCGSK3BNTRK1PLK4
SCHEMBL7107704 0.88 AURKA (0.83) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12430660 0.87 AURKA (0.81) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12430665 0.86 AURKA (0.76) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12430717 0.85 AURKA (0.78) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12430719 0.85 AURKA (0.78) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12430716 0.84 AURKA (0.80) AURKASRCGSK3BNTRK1PLK4
SCHEMBL12510631 0.84 AURKA (0.88) AURKASRCGSK3BNTRK1PLK4
SCHEMBL22072049 0.83 ULK1 (0.72) AURKASRCGSK3BNTRK1PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKA 3/4885SRC 298/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.